James M. Cleary
Broad Institute · 777 works · 20,547 citations · h-index 54
Top works
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- Institutional implementation of clinical tumor profiling on an unselected cancer population
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
- Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
- O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
- Light sheds light on cancer--distinguishing malignant tumors from benign tissues and tumors.
- Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
- Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
- Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors
- Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
- A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.